Literature DB >> 14552082

Citrate anticoagulation and adverse events.

J De Vos1, R Hombrouckx.   

Abstract

Several patients with heparin intolerance were dialysed with tri-sodium citrate as anticoagulant without acute clinical problems (good tolerance). After some weeks however problems arose. In all patients an alkalosis developed: the pre dialysis bicarbonate level rose progressively from 27 mmol/l to 40 mmol/l. This could be tempered by lowering the dialysis fluid bicarbonate concentration from 37 mmol/l to 25 mmol/l. A second problem was a progressive rise in pre dialysis sodium level from a mean of 136 mmol/l to 150 mmol/l. Adapting the dialysis fluid sodium concentration from 140 mmol/l towards 132 mmol/l could solve this. The third problem was a progressive rise in serum aluminium level in patients from 3 microg/l to 38 microg/l. After excluding water, concentrate, dialysis fluid, drug intake, etc... as possible sources, we controlled the aluminium level in the glass bottle containing tri-sodium citrate. We noted the very high value of 35,300 microg/l. After replacing the glass bottles with polyvinylchloride bags with a negligible aluminium content, the serum aluminium levels returned back to normal. It is known that citrate chelates the aluminium present in the glass of bottles or vials.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14552082     DOI: 10.1111/j.1755-6686.2003.tb00289.x

Source DB:  PubMed          Journal:  EDTNA ERCA J        ISSN: 1019-083X


  2 in total

Review 1.  What are the anticoagulation options for intermittent hemodialysis?

Authors:  Andrew Davenport
Journal:  Nat Rev Nephrol       Date:  2011-07-05       Impact factor: 28.314

2.  Use of High-Flow Continuous Renal Replacement Therapy with Citrate Anticoagulation to Control Intracranial Pressure by Maintaining Hypernatremia in a Patient with Acute Brain Injury and Renal Failure.

Authors:  Joshua E Medow; Shalin R Sanghvi; R Michael Hofmann
Journal:  Clin Med Res       Date:  2014-12-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.